| . | No. (%) . | |||
|---|---|---|---|---|
| Variable . | Placebo (n = 51) . | Daptomycin (n = 53) . | Total (n = 104) . | P Value . |
| All-cause mortality (30 days) | 6 (11.8) | 8 (15.1) | 14 (13.5) | .62 |
| All-cause mortality (90 days) | 9 (17.7) | 10 (18.9) | 19 (18.3) | 1 |
| Relapsed bacteremia within 30 days (among those who survived bacteremia episode) | 0 (0) | 1 (1.9) | 1 (1.0) | 1 |
| Relapsed bacteremia within 90 days (among those who survived bacteremia episode) | 2 (3.9) | 2 (3.8) | 4 (3.8) | 1 |
| Embolic or metastatic MSSA disease within 30 days | 9 (17.7) | 13 (24.5) | 22 (21.2) | .47 |
| Embolic or metastatic MSSA disease within 90 days | 9 (17.7) | 13 (24.5) | 22 (21.2) | .47 |
| Nephrotoxicity on presentation | 6 (11.8) | 9 (17.0) | 15 (14.4) | .57 |
| Nephrotoxicity on treatmenta,b | 13 (28.9) | 21 (47.7) | 34 (32.7) | .15 |
| Hepatotoxicity b | 3 (5.88) | 2 (3.77) | 5 (4.8) | .675 |
| Rhabdomyolysis b | 3 (5.88) | 0 (0) | 3 (2.9) | 0.11 |
| . | No. (%) . | |||
|---|---|---|---|---|
| Variable . | Placebo (n = 51) . | Daptomycin (n = 53) . | Total (n = 104) . | P Value . |
| All-cause mortality (30 days) | 6 (11.8) | 8 (15.1) | 14 (13.5) | .62 |
| All-cause mortality (90 days) | 9 (17.7) | 10 (18.9) | 19 (18.3) | 1 |
| Relapsed bacteremia within 30 days (among those who survived bacteremia episode) | 0 (0) | 1 (1.9) | 1 (1.0) | 1 |
| Relapsed bacteremia within 90 days (among those who survived bacteremia episode) | 2 (3.9) | 2 (3.8) | 4 (3.8) | 1 |
| Embolic or metastatic MSSA disease within 30 days | 9 (17.7) | 13 (24.5) | 22 (21.2) | .47 |
| Embolic or metastatic MSSA disease within 90 days | 9 (17.7) | 13 (24.5) | 22 (21.2) | .47 |
| Nephrotoxicity on presentation | 6 (11.8) | 9 (17.0) | 15 (14.4) | .57 |
| Nephrotoxicity on treatmenta,b | 13 (28.9) | 21 (47.7) | 34 (32.7) | .15 |
| Hepatotoxicity b | 3 (5.88) | 2 (3.77) | 5 (4.8) | .675 |
| Rhabdomyolysis b | 3 (5.88) | 0 (0) | 3 (2.9) | 0.11 |
Abbreviations: MSSA, methicillin-susceptible Staphylococcus aureus.
aExcluding patients who had evidence of nephrotoxicity on presentation.
bWithin 5 days of patient enrollment into the study.
| . | No. (%) . | |||
|---|---|---|---|---|
| Variable . | Placebo (n = 51) . | Daptomycin (n = 53) . | Total (n = 104) . | P Value . |
| All-cause mortality (30 days) | 6 (11.8) | 8 (15.1) | 14 (13.5) | .62 |
| All-cause mortality (90 days) | 9 (17.7) | 10 (18.9) | 19 (18.3) | 1 |
| Relapsed bacteremia within 30 days (among those who survived bacteremia episode) | 0 (0) | 1 (1.9) | 1 (1.0) | 1 |
| Relapsed bacteremia within 90 days (among those who survived bacteremia episode) | 2 (3.9) | 2 (3.8) | 4 (3.8) | 1 |
| Embolic or metastatic MSSA disease within 30 days | 9 (17.7) | 13 (24.5) | 22 (21.2) | .47 |
| Embolic or metastatic MSSA disease within 90 days | 9 (17.7) | 13 (24.5) | 22 (21.2) | .47 |
| Nephrotoxicity on presentation | 6 (11.8) | 9 (17.0) | 15 (14.4) | .57 |
| Nephrotoxicity on treatmenta,b | 13 (28.9) | 21 (47.7) | 34 (32.7) | .15 |
| Hepatotoxicity b | 3 (5.88) | 2 (3.77) | 5 (4.8) | .675 |
| Rhabdomyolysis b | 3 (5.88) | 0 (0) | 3 (2.9) | 0.11 |
| . | No. (%) . | |||
|---|---|---|---|---|
| Variable . | Placebo (n = 51) . | Daptomycin (n = 53) . | Total (n = 104) . | P Value . |
| All-cause mortality (30 days) | 6 (11.8) | 8 (15.1) | 14 (13.5) | .62 |
| All-cause mortality (90 days) | 9 (17.7) | 10 (18.9) | 19 (18.3) | 1 |
| Relapsed bacteremia within 30 days (among those who survived bacteremia episode) | 0 (0) | 1 (1.9) | 1 (1.0) | 1 |
| Relapsed bacteremia within 90 days (among those who survived bacteremia episode) | 2 (3.9) | 2 (3.8) | 4 (3.8) | 1 |
| Embolic or metastatic MSSA disease within 30 days | 9 (17.7) | 13 (24.5) | 22 (21.2) | .47 |
| Embolic or metastatic MSSA disease within 90 days | 9 (17.7) | 13 (24.5) | 22 (21.2) | .47 |
| Nephrotoxicity on presentation | 6 (11.8) | 9 (17.0) | 15 (14.4) | .57 |
| Nephrotoxicity on treatmenta,b | 13 (28.9) | 21 (47.7) | 34 (32.7) | .15 |
| Hepatotoxicity b | 3 (5.88) | 2 (3.77) | 5 (4.8) | .675 |
| Rhabdomyolysis b | 3 (5.88) | 0 (0) | 3 (2.9) | 0.11 |
Abbreviations: MSSA, methicillin-susceptible Staphylococcus aureus.
aExcluding patients who had evidence of nephrotoxicity on presentation.
bWithin 5 days of patient enrollment into the study.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
